LAM Cells as Potential Drivers of Senescence in Lymphangioleiomyomatosis Microenvironment

Int J Mol Sci. 2022 Jun 24;23(13):7040. doi: 10.3390/ijms23137040.

Abstract

Senescence is a stress-response process characterized by the irreversible inhibition of cell proliferation, associated to the acquisition of a senescence-associated secretory phenotype (SASP), that may drive pathological conditions. Lymphangioleiomyomatosis (LAM) is a rare disease in which LAM cells, featuring the hyperactivation of the mammalian Target of Rapamycin Complex 1 (mTORC1) for the absence of tuberin expression, cause the disruption of the lung parenchyma. Considering that LAM cells secrete SASP factors and that mTOR is also a driver of senescence, we deepened the contribution of senescence in LAM cell phenotype. We firstly demonstrated that human primary tuberin-deficient LAM cells (LAM/TSC cells) have senescent features depending on mTOR hyperactivation, since their high positivity to SA-β galactosidase and to phospho-histone H2A.X are reduced by inducing tuberin expression and by inhibiting mTOR with rapamycin. Then, we demonstrated the capability of LAM/TSC cells to induce senescence. Indeed, primary lung fibroblasts (PLFs) grown in LAM/TSC conditioned medium increased the positivity to SA-β galactosidase and to phospho-histone H2A.X, as well as p21WAF1/CIP1 expression, and enhanced the mRNA expression and the secretion of the SASP component IL-8. Taken together, these data make senescence a novel field of study to understand LAM development and progression.

Keywords: LAM; SASP; mTOR; senescence; tuberin.

MeSH terms

  • Cellular Senescence / genetics
  • Histones
  • Humans
  • Lymphangioleiomyomatosis* / metabolism
  • TOR Serine-Threonine Kinases / metabolism
  • Tuberous Sclerosis Complex 2 Protein / metabolism
  • Tumor Microenvironment
  • beta-Galactosidase / metabolism

Substances

  • beta-Galactosidase
  • Histones
  • TOR Serine-Threonine Kinases
  • Tuberous Sclerosis Complex 2 Protein